Table 1.
Clinicopathological features of the entire cohort of patients.
| Patient characteristics | All | HGSC | CCC | EC | |
|---|---|---|---|---|---|
| n. (%) | n. (%) | n. (%) | n. (%) | ||
| All | 97 (100) | 59 (61) | 18 (19) | 20 (21) | |
| Age | |||||
| median (IQR) | 58 (49–69) | 61 (49–70) | 56 (49–68.25) | 53.5 (46–60) | |
| Menopause | |||||
| no | 31 (32) | 16 (27) | 6 (33) | 9 (45) | |
| yes | 64 (66) | 41 (69) | 12 (67) | 11 (55) | |
| NA | 2 (2) | 2 (3) | 0 (0) | 0 (0) | |
| FIGO Stage | |||||
| I–II | 37 (38) | 7 (12) | 13 (72) | 17 (85) | |
| III–IV | 60 (62) | 52 (88) | 5 (28) | 3 (15) | |
| Residual tumor | |||||
| No | 52 (54) | 18 (31) | 15 (83) | 20 (100) | |
| Yes | 44 (45) | 41 (69) | 3 (17) | 0 (0) | |
| NA | 1 (1) | 0 (0) | 0 (0) | 0 (0) | |
| Peritoneal cytology | |||||
| negative | 38 (39) | 12 (20) | 11 (61) | 15 (75) | |
| positive | 55 (57) | 47 (80) | 6 (33) | 3 (15) | |
| NA | 4 (4) | 0 (0) | 1 (6) | 2 (10) | |
| Chemotherapy response | |||||
| not response/partial | 16 (16) | 12 (20) | 4 (22) | 0 (0) | |
| complete | 77 (79) | 46 (78) | 14 (78) | 17 (85) | |
| NA | 4 (4) | 1 (2) | 0 (0) | 3 (15) | |
| Platinum sensitivity | |||||
| resistant | 15 (15) | 15 (25) | 0 (0) | 0 (0) | |
| partial sensitive | 16 (16) | 9 (15) | 6 (33) | 1 (5) | |
| sensitive | 62 (64) | 34 (58) | 12 (67) | 16 (80) | |
| NA | 4 (4) | 1 (2) | 0 (0) | 3 (15) | |
| Platinum re-eligibility | |||||
| no | 19 (32) | 19 (32) | – | – | |
| yes | 39 (66) | 39 (66) | – | – | |
| NA | 1 (2) | 1 (2) | – | – | |
| CD3 (cells/mm2) | |||||
| μg | 97 | 130 | 42 | 86 | |
| CD163 (cells/mm2) | |||||
| μg | 365 | 446 | 285 | 253 | |
HGSC, High-Grade Serous Carcinoma; CCC, Clear Cell Carcinoma; EC, Endometrioid Carcinoma; IQR, interquartile range; NA, not available; μg, geometric mean.